Abstract: A fiber optic cable and connector assembly is disclosed. The assembly includes a cable optical fiber, a ferrule, a stub optical fiber having a first portion supported within the ferrule a second portion the projects rearwardly the ferrule and a signal modification structure optically coupled between the stub optical fiber and the cable optical fiber.

Abstract: The present invention is a metal cable locking mechanism for allowing the cable to pass through the locking mechanism in one direction but grips the metal cable when it is attempted to be removed from the locking mechanism in the opposite direction. The locking mechanism includes a housing having a through passageway for receiving the cable, a tapering internal cavity, wherein a wheel and spring are positioned within the internal cavity, the spring biasing the wheel toward a narrower end of the internal cavity. The wheel is wedged between the cable and an internal cavity ramp whenever a force is applied to the cable attempting to withdraw the cable. A releasing device can be manually inserted into a slot passage to force the wheel away from the narrower end of the internal cavity so that the locking mechanism will ungrasp the cable.

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Abstract: The present invention provides, in part, heterocyclic spiro compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: A fiber-optic connector ferrule body (10) that includes a depth that extends from a front end (12) to a rear end (14) of the ferrule. The ferrule includes a contact face (16) at the front end of the ferrule. The contact face includes a major dimension that extends along a major axis (X) defined by the contact face and a minor dimension that extends along a minor axis (Y) defined by the contact face. The major and minor axes are perpendicular to one another. The ferrule also defines alignment pin receivers (18) that extend rearwardly from the front end of the ferrule. The alignment pin receivers have tight-fit sections (26) that extend into the ferrule body from the contact face and flex sections (28) that extend from the first transverse cross-sectional shape to the rear end. The first and second transverse cross-sectional profiles define a degree of rotational flexibility between alignment pins (24) received in the alignment pin receivers (18) and the ferrule body (10).

Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (?-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.

Abstract: A method for positioning an optical fiber having an end portion within an alignment groove of an alignment device includes orienting the optical fiber in the alignment groove of the alignment device; causing the optical fiber to elastically flex; using an interference point to assist in forming a curved profile of the flexed fiber, and using inherent elasticity of the flexed optical fiber to assist in retaining the end portion of the optical fiber in contact with the alignment groove. A connection system includes a connector, alignment device, and adapter, with an interference point on at least one of the connector, alignment device, or adapter.

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.

Abstract: A system is described for controlling an actuating unit that restricts physical access such as a motorized garage door actuator unit. The system comprises a mobile wireless communication device, an electro-mechanical access control security device, and a receiving unit controlling the electro-mechanical access control security device, the receiving unit paired with the mobile wireless communication device for receiving user input for activating the electro-mechanical access control security device via a peer-to-peer communication directly with the mobile wireless communication device, and a pre-authorization of communication of the receiving unit with the mobile wireless communication device, the mobile wireless communication device receiving the pre-authorization from a central security server.

Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2, R3, R4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.

Abstract: An encrypted security system and associated methods for controlling physical access. The system includes a security server configured to receive a request for authentication from a mobile device, the request comprising information identifying the mobile device and a physical access control device. The security server forwards an encryption message comprising a plurality of unique identifiers to the physical access control device via the mobile device. The physical access control device is configured to authenticate the plurality of unique identifiers in the encryption message and operate an access control mechanism.

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Abstract: A method for positioning an optical fiber having an end portion within an alignment groove of an alignment device includes orienting the optical fiber in the alignment groove of the alignment device; causing the optical fiber to elastically flex; using an interference point to assist in forming a curved profile of the flexed fiber, and using inherent elasticity of the flexed optical fiber to assist in retaining the end portion of the optical fiber in contact with the alignment groove. A connection system includes a connector, alignment device, and adapter, with an interference point on at least one of the connector, alignment device, or adapter.

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.

Abstract: Bioactive liquid formulations are formed of combinations of absorbable, segmented aliphatic polyurethane compositions and liquid polyether for use as vehicles for the controlled release of at least one active agent for the conventional and unconventional treatment of different forms of cancer and the management of at least one type of bacterial, fungal, and viral infection.

Abstract: A vehicle access and control system includes an activation system, a vehicle control system, a communication system provided in the vehicle, a computer system mounted in the vehicle, and a vehicle access control system including a processor, a non-volatile memory, and a set of instructions stored on the non-volatile memory. The set of instructions, when executed by the processor, causing the processor to receive a user specific identification input, access a user profile associated with the user specific identification input, determine, from the user profile, system permissions associated with the user specific identification input, and manage access to one or more of the activation system, vehicle control system, communication system, and the computer system based on the system permissions.